8-K: Crinetics: PALSONIFY Launch Exceeds $5M, Atumelnant CAH Positive

Crinetics Pharmaceuticals announced preliminary Q4 2025 PALSONIFY revenue exceeding $5 million and positive Phase 2 results for atumelnant in congenital adrenal hyperplasia.

Summary

• Preliminary and unaudited net product revenue from PALSONIFY (paltusotine) is expected to be over $5.0 million for the three months ended December 31, 2025.
• Over 200 enrollment forms for PALSONIFY have been received as of December 31, 2025, including 22 from U.S.-based open-label extension participants.
• More than 125 unique PALSONIFY prescribers have been identified, with an even split (50%/50%) between community and pituitary treatment center settings.
• Approximately half of newly filled PALSONIFY bottles were reimbursed without the need for Quickstart bridge supplies, and most prior authorizations have a 12-month duration.
• Atumelnant Phase 2 Cohort 4 data for congenital adrenal hyperplasia (CAH) showed rapid, sustained lowering of androstenedione (A4) in all 8 patients who completed the cohort.
• Seven out of these 8 patients continued to maintain lower A4 after glucocorticoid (GC) doses were reduced to physiologic levels.
• Atumelnant was well-tolerated in Cohort 4 and the Open-Label Extension (OLE), with no serious adverse events, no treatment-related severe adverse events, and no hepatic transaminase adverse events.
• Interim OLE data from the first 7 patients completing 13 weeks showed serum A4 reductions and GC dose reductions consistent with Cohort 4 results.

Sentiment

Score: 8

Explanation: The filing reports strong initial commercial success for PALSONIFY and highly positive clinical data for atumelnant, indicating significant progress in both commercialization and pipeline development. The safety profile of atumelnant is also favorable. The only cautionary notes are the preliminary nature of financial data and standard forward-looking statement risks.

Positives

• PALSONIFY achieved preliminary net product revenue of over $5.0 million in Q4 2025, indicating a strong initial commercial launch.
• High patient and prescriber uptake for PALSONIFY, with over 200 enrollment forms and more than 125 unique prescribers, demonstrating market acceptance.
• Favorable payer feedback for PALSONIFY, with approximately half of new prescriptions reimbursed without bridge supplies and most prior authorizations lasting 12 months.
• Atumelnant demonstrated a rapid and sustained 67% mean reduction in androstenedione (A4) levels in CAH patients in Phase 2 Cohort 4.
• Atumelnant enabled 88% (7 out of 8) of patients in Cohort 4 to reduce glucocorticoid doses to physiologic levels while maintaining lower A4, a significant clinical benefit.
• Atumelnant showed a favorable safety profile across all Phase 2 cohorts and the Open-Label Extension, with no serious adverse events or hepatic transaminase adverse events, and over 750 weeks of cumulative adult CAH patient exposure.

Risks

• Preliminary and unaudited financial estimates may differ materially from actual financial results upon completion of financial closing procedures and audit.
• Clinical study data reported may change following completion or a more comprehensive review of the data.
• Inability to obtain, maintain, and enforce patents and other intellectual property rights, or the potential for prohibitively difficult or costly protection of such rights.
• Geopolitical events may disrupt business operations, clinical studies, manufacturing, supply chain, or impair employee productivity.
• Unexpected adverse side effects or inadequate efficacy of product candidates could limit their development, regulatory approval, and/or commercialization.
• Dependence on third parties for product manufacturing, research, and preclinical and clinical testing poses operational risks.
• Clinical and preclinical studies may not proceed at the expected time, in the expected manner, or at all.
• The timing and outcome of research, development, and regulatory review are uncertain, and drug candidates may not advance in development.
• Capital resources may be used sooner than expected, or the cash burn rate may accelerate.
• Regulatory developments or political changes, including policies related to pricing and pharmaceutical drug reimbursement, in the United States and foreign countries could negatively impact business.

Future Outlook

Crinetics plans to initiate a Phase 3 program for atumelnant for CAH and a Phase 2/3 program for atumelnant for ACTH-dependent Cushing's syndrome. The company expects additional research pipeline updates and the advancement of those programs, aiming to become a premier global endocrine company and redefine the standard of care for endocrine and endocrine-related diseases.

Management Comments

• "I'm very proud of our team's strong execution of Palsonify's launch in acromegaly. We are delivering impressive results, highlighted by over 200 enrollment forms in the first three months after FDA approval, a broad prescriber base, and continued momentum toward favorable payer coverage." Scott Struthers, Ph.D., founder and chief executive officer of Crinetics.
• "Further, we are excited to announce additional positive atumelnant clinical data which reinforces its potential to become an uncompromising, highly differentiated treatment for people struggling with CAH." Scott Struthers, Ph.D.
• "Today's launch update and clinical results mark two major steps forward for becoming the premier global endocrine company and to advance our unique portfolio that has been purposefully built to redefine the standard of care for people struggling with endocrine and endocrine-related diseases." Scott Struthers, Ph.D.

Industry Context

The strong initial commercial performance of PALSONIFY positions Crinetics as a significant competitor in the acromegaly market, offering a differentiated oral treatment option against established injectable somatostatin receptor ligands. The positive atumelnant data for CAH suggests a potential breakthrough in a condition with high unmet need, where existing adjunctive therapies have struggled to consistently maintain androgen reduction while allowing for glucocorticoid dose tapering. Atumelnant's mechanism of action, selectively blocking ACTH at the adrenal cortex, could offer a superior approach to managing CAH by decoupling androgen control from glucocorticoid replacement.

Comparison to Industry Standards

• Atumelnant's ability to achieve a 67% mean reduction in androstenedione (A4) levels while simultaneously enabling 88% of patients to reduce glucocorticoid doses to physiologic levels in Phase 2 Cohort 4 appears to offer a more comprehensive benefit compared to an FDA-approved CRF1 antagonist, which did not maintain A4 reductions as glucocorticoid doses were reduced.
• The sustained A4 reduction and successful glucocorticoid dose reduction observed with atumelnant in Cohort 4 and the Open-Label Extension, coupled with a favorable safety profile and no hepatic transaminase adverse events, suggests a potentially superior benefit/risk profile for CAH treatment compared to other investigational or approved therapies that may have limitations in maintaining efficacy during glucocorticoid tapering or present different safety concerns.

Stakeholder Impact

• Shareholders: Positive impact due to strong commercial launch of PALSONIFY and promising clinical data for atumelnant, potentially increasing future revenue and pipeline value.
• Patients (Acromegaly): PALSONIFY offers a new, convenient oral treatment option, potentially improving quality of life and treatment adherence.
• Patients (CAH): Atumelnant shows potential for a transformative treatment that could normalize hormone levels and reduce reliance on high glucocorticoid doses, improving long-term health outcomes and reducing side effects.
• Healthcare Providers: PALSONIFY's broad prescriber base indicates acceptance and utility in clinical practice. Atumelnant could provide a highly differentiated treatment tool for CAH, addressing unmet needs.

Next Steps

• Completion of Crinetics' financial closing procedures and audit for the year ended December 31, 2025.
• Initiation of a Phase 3 program for atumelnant for congenital adrenal hyperplasia (CAH).
• Initiation of a Phase 2/3 program of atumelnant for ACTH-dependent Cushing's syndrome.
• Further clinical development of other drug candidates in the pipeline.
• Additional research pipeline updates.

Key Dates

Recommendation

The company has demonstrated strong commercial execution with PALSONIFY, exceeding initial revenue expectations for its first full quarter post-FDA approval. This indicates successful market penetration and positive physician/payer reception. Concurrently, the positive Phase 2 data for atumelnant in CAH, particularly its ability to reduce A4 levels while allowing for glucocorticoid dose reduction with a clean safety profile, positions it as a highly promising late-stage asset with significant market potential. These dual catalysts, commercial success and strong clinical pipeline progression, suggest substantial upside for the stock, warranting a strong buy recommendation for long-term investors.

Keywords

Crinetics Pharmaceuticals, CRNX, PALSONIFY, paltusotine, acromegaly, atumelnant, congenital adrenal hyperplasia, CAH, ACTH antagonist, Phase 2 trial, commercial launch, net product revenue, clinical trial results, endocrinology, rare disease, biopharmaceutical